vimarsana.com
Home
Live Updates
Phase 3 Trial of AXS-12 for Narcolepsy Meets Primary Endpoin
Phase 3 Trial of AXS-12 for Narcolepsy Meets Primary Endpoin
Phase 3 Trial of AXS-12 for Narcolepsy Meets Primary Endpoint
The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo.
Related Keywords
Herriot Tabuteau ,
Michael Thorpy ,
Wake Disorders Center ,
Albert Einstein College Of Medicine ,
Montefiore Medical Center ,
Orphan Drug Designation ,
Sleep Wake Disorders Center ,
Albert Einstein College ,
Axsome Therapeutics ,
Accessed March ,